Payment overview · 2025
General Payments
$720.98
43 reported records · 9 companies
Healthcare provider profile · identity verified
Joseph J Brignola, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NUTLEY, NJ · NPI 1508824897
Verified facts
What the public records show
CMS Open Payments records show Joseph J Brignola, MD received $720.98 in general payments during 2025 across 43 reported records.
Novo Nordisk Inc accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ATACAND as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Atacand by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $214.64 | 29.8% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.49 | 27.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.08 | 14.8% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.28 | 7.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.67 | 6.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.06 | 6.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.58 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.27 | 2.3% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $15.91 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $720.98 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $155.51 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.84 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $93.99 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.76 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.76 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.50 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ATACAND open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1206448957 |
Atacand · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 586 | 90 |
| Metformin Hcl | Metformin Hcl | 256 | 46 |
| Carvedilol | Carvedilol | 244 | 12 |
| Donepezil Hcl | Donepezil Hcl | 240 | suppressed |
| Losartan Potassium | Losartan Potassium | 235 | 41 |
| Potassium Chloride | Potassium Chloride | 235 | 13 |
| Sertraline Hcl | Sertraline Hcl | 231 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 227 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 13 |
| Divalproex Sodium | Divalproex Sodium | 225 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 41 |
| Lisinopril | Lisinopril | 196 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 12 |
| Xarelto | Rivaroxaban | 173 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 31 |
| Furosemide | Furosemide | 165 | 18 |
| Alprazolam | Alprazolam | 159 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 15 |
| Eliquis | Apixaban | 145 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | suppressed |
| Mirtazapine | Mirtazapine | 136 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 130 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 126 | suppressed |
| Levetiracetam | Levetiracetam | 125 | suppressed |
| Gabapentin | Gabapentin | 116 | 11 |
| Midodrine Hcl | Midodrine Hcl | 111 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 107 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 12 |
| Ezetimibe | Ezetimibe | 106 | 14 |
| Simvastatin | Simvastatin | 104 | 15 |
| Anastrozole | Anastrozole | 92 | suppressed |
| Meloxicam | Meloxicam | 92 | 12 |
| Prednisone | Prednisone | 83 | 20 |
| Baclofen | Baclofen | 78 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Valsartan | Valsartan | 65 | suppressed |
| Clonazepam | Clonazepam | 62 | suppressed |
| Atenolol | Atenolol | 61 | suppressed |
| Colchicine | Colchicine | 61 | suppressed |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Finasteride | Finasteride | 58 | suppressed |
| Bupropion Xl | Bupropion Hcl | 57 | suppressed |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 12 |
| Glimepiride | Glimepiride | 51 | 17 |
| Torsemide | Torsemide | 51 | suppressed |
| Calcium Acetate | Calcium Acetate | 50 | suppressed |
| Brilinta | Ticagrelor | 49 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 49 | suppressed |
| Nifedipine Er | Nifedipine | 49 | suppressed |
| Omeprazole | Omeprazole | 49 | 12 |
| Glatopa | Glatiramer Acetate | 48 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Pentoxifylline | Pentoxifylline | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 37 | 29 |
| Cefuroxime | Cefuroxime Axetil | 37 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Mesalamine | Mesalamine | 35 | suppressed |
| Acetazolamide | Acetazolamide | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 20 |
| Aptiom | Eslicarbazepine Acetate | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 20 |
| Famotidine | Famotidine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Atacand | Candesartan Cilexetil | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Qulipta | Atogepant | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ritonavir | Ritonavir | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $720.98 · 43 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, Fibroscan, JARDIANCE, MOUNJARO, Ozempic, PAXLOVID, PREVNAR 20, REXULTI, Rybelsus, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error